Volume 224 - Issue 3
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Authors: Gin S. Malhi, Erica Bell, Kinga Szymaniak, Philip M. Boyce, Jeffrey C. L. Looi
Correspondence: gin.malhi@sydney.edu.au
Med J Aust 2026 || doi: 10.5694/mja2.70155
Published online: 3 March 2026
Published online: 3 March 2026
Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia
Lan Gao, Rosie Watson, Nawaf Yassi
Uptake and Costs of the 60-Day Dispensing Policy for Antihypertensive Medicines in Australia: A Mixed Methods Study
Tian Wang, Huy L. Nguyen, Isabella Tan, Dean S. Picone, Emily Atkins, Sonali R. Gnanenthiran, Michael O. Falster, Sallie-Anne Pearson, Anthony Rodgers, Aletta E. Schutte
Antidepressant Prescribing in Australian Primary Care: Time to Reevaluate
Katharine A. Wallis, Joanna Moncrieff
Valproate Prescribing for Female Adolescents and Management of the Associated Teratogenicity Risk, Royal Children's Hospital, Melbourne, 2022–2024: A Retrospective Audit of Medical Records Data
Briana Davis, Monica S. Cooper, Michael South, Jeremy L. Freeman, Emma Macdonald-Laurs
Medications for early treatment of COVID‐19 in Australia
Adam Polkinghorne, James M Branley
Nocebo effects in practice: methotrexate myths and misconceptions
Mark H Arnold, Jane Bleasel, Inam Haq